KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Convertible Debt (2016 - 2025)

Pacira BioSciences has reported Convertible Debt over the past 13 years, most recently at $280.3 million for Q2 2025.

  • Quarterly results put Convertible Debt at $280.3 million for Q2 2025, down 41.56% from a year ago — trailing twelve months through Jun 2025 was $280.3 million (down 41.56% YoY), and the annual figure for FY2024 was $279.3 million, down 29.92%.
  • Convertible Debt for Q2 2025 was $280.3 million at Pacira BioSciences, roughly flat from $279.8 million in the prior quarter.
  • Over the last five years, Convertible Debt for PCRX hit a ceiling of $479.5 million in Q2 2024 and a floor of $278.9 million in Q3 2024.
  • Median Convertible Debt over the past 5 years was $397.7 million (2023), compared with a mean of $362.0 million.
  • Biggest five-year swings in Convertible Debt: grew 26.97% in 2022 and later plummeted 41.56% in 2025.
  • Pacira BioSciences' Convertible Debt stood at $339.3 million in 2021, then rose by 19.31% to $404.8 million in 2022, then dropped by 1.53% to $398.6 million in 2023, then decreased by 29.92% to $279.3 million in 2024, then rose by 0.33% to $280.3 million in 2025.
  • The last three reported values for Convertible Debt were $280.3 million (Q2 2025), $279.8 million (Q1 2025), and $279.3 million (Q4 2024) per Business Quant data.